INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
02/27/2026
Back to search
Official data from USPTO
E-PHARMA ALWAYS TO CREATE SOLUTIONS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
02/28/2026
Trademark type
Combined
Nice classes
5, 40, 42
Filing date
03/10/2017
Registration date
12/11/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/27/2025
Last transaction
02/28/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
09
Owner location
IT
Examiner
RICHARDS, LESLIE
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "E-PHARMA" in the color light blue placed above the stylized wording "ALWAYS TO CREATE SOLUTIONS" in the color white and enclosed in a light blue bar.
Holders and representatives
Holders
E-PHARMA TRENTO S.p.A.
Representatives
Perla M. Kuhn Fox Rothschild LLP
Technical classification
Nice Classes
Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of anemiacold and flugastro-intestinal diseasesosteroporosisrespiratory diseasesfor use in urologygynecological diseasecentral nervous system and for pain relief and food supplement in the form of effervescent tablets and/or granulated effervescent preparations manufactured on behalf on third parties; pharmaceutical preparations for the treatment of anemiacold and flugastro-intestinal diseasesosteroporosisrespiratory diseasesfor use in urologygynecological diseasecentral nervous system and for pain relief and food supplement in the form of orally disintegrating tablets and orally disintegrating granules and soluble granules manufactured on behalf of third parties; pharmaceutical preparations for the treatment of anemiacold and flugastro-intestinal diseasesosteroporosisrespiratory diseasesfor use in urologygynecological diseasecentral nervous system and for pain relief and food supplement in the form of granules for suspension and chewable tablets manufactured on behalf of third parties
Class 40
Processing of chemical and/or pharmaceutical substances into effervescent tabletsgranulated effervescent preparationsorally disintegrating tabletsorally disintegrating granulessoluble granulesgranules for suspensionchewable tablets
Class 42
Research and development of pharmaceutical preparations and food integrators in the form of effervescent tabletsgranulated effervescent preparationsorally disintegrating tabletsorally disintegrating granulessoluble granulesgranules for suspensionchewable tablets; scientific and industrial research in the field of chemistry and pharmacology; scientific analytical laboratory services; chemical research and analysis
Publications
History of USPTO decisions and trademark events.
28 publications found
C71T
CANCELLED SECTION 71
06/27/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
12/11/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/05/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/19/2019
FIMP
FINAL DISPOSITION PROCESSED
03/19/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/11/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
12/11/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/25/2018
PUBO
PUBLISHED FOR OPPOSITION
09/25/2018
GPNX
NOTIFICATION PROCESSED BY IB
09/21/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/05/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/05/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/05/2018
ALIE
ASSIGNED TO LIE
08/20/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/07/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/03/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/02/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/02/2018
RFNT
REFUSAL PROCESSED BY IB
01/19/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/03/2018
RFRR
REFUSAL PROCESSED BY MPU
01/03/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/22/2017
CNRT
NON-FINAL ACTION WRITTEN
12/21/2017
MAFR
APPLICATION FILING RECEIPT MAILED
12/19/2017
DOCK
ASSIGNED TO EXAMINER
12/15/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/15/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/14/2017
Continuous trademark protection
Get notified about every new filing that threatens E-PHARMA ALWAYS TO CREATE SOLUTIONS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.